MSH2 and cancer: The germ-line analysis of patients with MSH2-negative malignant neoplasms uses NGS and an exon-level array comparative genomic hybridization–based or multiplex ligation-dependent probe amplification (MLPA)-based deletion/duplication analysis of all exons and adjacent noncoding regions [48].